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ABSTRACT. Oligoribonucleotide conjugates carrying apolar carbohydrates at the 5′-end and the 
corresponding siRNA duplexes have been prepared using phosphoramidite chemistry. All the 
carbohydrate-siRNA derivatives were compatible with RNA interference machinery if 
transfected with oligofectamine. In the absence of a transfection agent, some of them exerted 
certain reduction of gene expression. Double-tailed permethylated glucose conjugated to 
siRNA through a long spacer inhibited gene expression up to 26% compared to the scrambled 
duplex. Such modifications contribute positively to the stability of oligoribonucleotides against 
5'-exonuclease degradation. 
Oligonucleotides have shown great potential as therapeutic agents by different mechanisms 
[1] especially small interfering RNA duplex (siRNA) [2]. However, the drug potential of siRNAs is 
still limited due to low stability and inefficient delivery [3]. To increase its stability towards 
nuclease degradation and increase cellular uptake, modified oligonucleotides and conjugation 
of siRNA to different delivery carriers such as antibodies, lipids, polymers, peptides or 
carbohydrates have been reported [4]. Among them, lipids are being widely studied and 
cholesterol conjugates have been tested in vivo showing promising results [5]. Conjugation to 
lipophilic molecules introduces a partial hydrophobic character to the bioconjugates which 
may enhance their cellular uptake not only by increased membrane permeability but also 
through receptor mediated endocytosis [6]. Some hydrophobic modifications used on siRNA 
with some success are shown in Figure 1. 
We recently reported the synthesis of glucose oligonucleotide conjugates where the sugar was 
attached to the 5’- end of the DNA strand and had different spatial presentations [7]. Cell 
uptake studies using flow cytometric analysis showed that conjugates with the glucose moiety 
linked through long spacers (15 to 18 atom distances) were better internalized than those with 
short linkers (4 atom distance) or than DNA control strands without sugar modification.  
Then we synthesized carbohydrate-siRNA duplexes targeting tumor necrosis factor carrying 
one, two or four glucose and galactose residues at the 5’-end of the passenger strand. The 
modified siRNA duplexes have similar inhibitory properties than unmodified RNA duplexes in 
HeLa cells when transfected with oligofectamine [8]. Without transfection agent, glucose-
siRNA conjugates showed no inhibition whereas galactose-siRNA duplexes on HuH-7 cells 
which possess abundant asialoglycoprotein receptors displayed up to 25% anti-TNF inhibitory 
properties.  
Here, the idea was to examine apolar carbohydrates linked to siRNA duplexes as new 
hydrophobic platforms that may improve the oligoribonucleotide cell uptake without 
disrupting the RNAi machinery during gene inhibition. The design consisted of per- methylated 
glucose attached to the 5’-end of the passenger strand of the siRNA via two different spacers, 
a short ethylene glycol and a long dodecanodiol (Figure 2). A dendron scaffold was also used 
since it has been demonstrated that lipid-oligonucleotide conjugates presenting double-tailed 
lipid modifications show good results in cellular uptake [9]. A spacer-oligonucleotide conjugate 
was also prepared as a negative control. 
Figure 1. Lipophilic vectors used in the literature to improve siRNA cell uptake. Soutschek et al. 
(2004) used a cholesterol, Godeau et al. (2008) used a fatty alcohol, MacKellar et al. (1992) 
used a double aliphatic alcohol and Nishina et al. (2008) used an alpha-tocopherol. 
 
Figure 2. Structure of the carbohydrate oligoribonucleotide conjugates prepared in this study. 
RNA sequence is the passenger sequence: 5’-AUCUGAAGAAGGAGAAAAATT-3’.  The RNA 
sequence of the guide is: 5'-UUUUUCUCCUUCUUCAGAUTT-3'.  
 
 
Synthesis. We synthesized carbohydrate-RNA conjugates using standard solid-phase 
oligonucleotide automatic synthesis using the corresponding apolar carbohydrate 
phosphoramidites (Scheme 1).  The preparation of permethylated glucose phosphoramidite 
derivative 6 containing the short spacer was carried out following the same methodology 
described previously by our group [10]. This strategy was extended to the apolar sugar with 
the long dodecanodiol spacer [11]. Briefly, glycosylation of the O-benzyl protected 
dodecanodiol spacer with -bromoacetoglucose 7 resulted in compound 8 in 62% yield. 
Deprotection of the acetyl groups followed by methylation under standard conditions 
produced compound 9 in good overall yield (78%, 2 steps). Then, hydrogenation and standard 
phosphoramidite preparation were carried out yielding permethylated glucose 
phosphoramidite 11 (67 and 74%, respectively). We also prepared a permethylated cellobiose 
phosphoramidite 12 and a perbutylated glucose phosphoramidite 13, both with the long 
spacer following the same synthetic strategy. A dodecanol phosphoramidite control 14 was 
also synthesized from 1-dodecanol as described previously [11]. 
RNA synthesis. The siRNA sequences designed to target Renilla Luciferase gene were 5’-
AUCUGAAGAAGGAGAAAAATT-3’ as the passenger sequence and 5'-
UUUUUCUCCUUCUUCAGAUTT-3' as the guide sequence. Oligoribonucleotide conjugates (1-4) 
were prepared using a DNA synthesizer. Apolar sugar phosphoramidites were added at the last 
step on the RNA synthesis. Oligonucleotides presented a major peak in HPLC chromatograms 
with some impurities but they were easily separated by HPLC obtaining the desired conjugates. 
However, isolation of siRNA conjugates containing permethylated cellobiose or perbutylated 
glucose, both with the long spacer, was not successful due to problems either during coupling 
with the corresponding phosphoramidites or during the cleavage and deprotection steps. 
Oligoribonucleotide sequences carrying apolar carbohydrates at the 5’-end of the passenger 




Scheme 1. Synthesis of permethylated glucose phosphoramidite derivatives 6 and 11. 
Compound 6 was synthesized as described in ref. 9. Reagents and conditions: a) 1,12-
dodecanediol, monobenzyl ether, Ag2CO3, CH2Cl2; b) Na2CO3, MeOH; c) MeI, NaH, DMF; d) H2, 
Pd(OH)2, THF/MeOH; e) ) 2-cyanoethyl-N,N'-diisopropylamino-chlorophosphoramidite, DIPEA, 
CH2Cl2. 
 
Dual-luciferase assay. After RNA synthesis, we evaluated the effect of the above described 5'-
sense-carbohydrate-modified siRNAs on the ability of the corresponding conjugate derivatives 
to act as inhibitors of gene expression. Furthermore, we tested the ability of such conjugates 
to impart cell uptake. We carried out separate gene knockdown experiments in HeLa cells. In a 
first series of experiments, the cells were cotransfected with two luciferase plasmids (Renilla 
and firefly; target and internal control, respectively), with siRNA duplexes containing each of 
the five modified passenger strands (1-4), and with the corresponding unmodified siRNA (wt). 
Cotransfection of plasmids and siRNAs was carried out by using commercial cationic liposomes 
(Lipofectamine 2000). Twenty-two hours after transfection, the luciferase activities of the 
samples were measured by using a luminometer. The results, showing Renilla luciferase 
activity normalized to firefly luciferase, are shown in Figure 3. Interestingly, the presence of 
permethylated glucoseC2, and permethylated glucoseC12 at the 5'-end of the passenger 
strand (1 and 2, respectively) did not disrupt RNAi activity. The corresponding siRNA 
conjugates showed activities comparable to the unmodified siRNA (wt) [(90±1)% knockdown of 
Renilla expression for unmodified wt versus (90±1)% and (89±1)% for 1 and 2, respectively]. 
Conjugation of permethylated glucoseC12-doubler and C12 spacer to the 5'-end of the sense 
strand siRNA (conjugates 3 and 4, respectively) caused a slight decrease in activity, but gene 
silencing activity of these siRNAs was still quite remarkable: [(71±1)% and (71±3)% for 3 and 4, 
respectively, versus (90±1)% for wt]. A sequence scrambled siRNA (as negative control) was 
used to ensure specificity.  Cells cotransfected with the scrambled siRNA showed levels of 
Renilla luciferase activity similar to those of cells transfected with plasmids alone. Thus, the 
results indicate that the siRNA 1-4 do specifically induce inhibition of expression of the target 
gene. 
Finally, in a second series of experiments we examined the ability of conjugates 1-4 to improve 
cell uptake in comparison to naked siRNA (Figure 4). Three hours after transfection of the two 
luciferase plasmids, the cell medium was discarded and the cells were incubated with fresh 
medium and the siRNA derivatives in the absence of Lipofectamine 2000 (750 nM siRNA 
conjugates). Twenty-two hours after transfection the luciferase activities were measured as 
described above. Although gene knockdown was significantly less efficient than that observed 
for siRNA-lipofectamine complexes, results showed that siRNA conjugates 3 and 4 were able to 
penetrate HeLa cells in the absence of a transfection agent [(15±3)% and (26±12)% knockdown 
of Renilla expression for 3 and 4, respectively, versus (2±2)% for wt)]. 
Nuclease-resistant properties. Since the above experiments showed that most of the 5'-
terminal modifications could mediate RNAi activity to levels comparable to wild type siRNA, 
and that some siRNA conjugates were able to penetrate the cell membrane, it was of interest 
to study the 5'-exonuclease resistance of these 5'-modified oligonucleotides. To carry out such 
studies, unmodified (wt) or 5'-modified passenger strands 1-4 were incubated with Bovine 
Spleen Phosphodiesterase (BSP). At various time points, aliquots of the reactions were 
withdrawn and the samples were analyzed by polyacrylamide gel electrophoresis (Figure 5). 
Unmodified passenger strand showed low stability, with only 5% of the original oligonucleotide 
strand remaining intact after 24 h of incubation with BSP. Permethylated glucose C12-doubler-
passenger 3 displayed a slight increase in stability, with 40% and 5% of the original 
oligonucleotide remaining intact through 24 and 48 h, respectively. Very interestingly, 
conjugation of C12 to the 5'-end of the passenger strand (5'-modified passenger strand 4) gave 
rise to a significant increase in stability, with 45% of the original strand remaining intact for 72 
h. Finally, permethylated glucose C2-modified and permethylated glucose C12-modified 
passenger strands 1 and 2 demonstrated even higher stability, with only 20% and 10% of 
degradation after 72 h. Further experiments should be made to understand the differences 
found between siRNAs. 
Figure 3. Reduction in Renilla luciferase activity of modified siRNAs 1-4 in Hela cells using 
oligofectamine as transfecting agent for siRNA. The cells were treated with 0.8 nM siRNA. 
Mean values (±SD) from three independent experiments are presented. 
 
 
Figure 4. Reduction in Renilla luciferase activity of modified siRNAs 1-4 in Hela cells in the 
absence of oligofectamine as transfecting agent for siRNA. The cells were treated with 750 nM 
siRNA. Mean values (±SD) from three independent experiments are presented. 
 
In conclusion, apolar carbohydrates covalently attached to the 5’-end of siRNA 
oligonucleotides have been synthesized. Three types of spacers, ethylene glycol, dodecanediol 
and dodecanediol symmetric doubler have been used. These modifications do not alter the 
RNAi machinery on HeLa cells. When siRNA modified conjugates were used without 
oligofectamine certain inhibition was observed. The best cellular uptake was observed for 
lipophilic-siRNA conjugates 3 and 4 inhibiting gene expression only up to 26% compared to the 
scrambled duplex. We also showed that conjugation of C12 spacer, C12-doubler, 
permethylated glucose C2 and permethylated glucose C12 units to the 5'-end of the passenger 
strand substantially enhanced resistance to 5'-exonuclease-catalyzed hydrolysis. Altogether, 
our data demonstrates that apolar carbohydrates are a new tool for the development of 
nucleic acids-based drugs with potential value in the preparation of formulations for 
intravenous administration as described for lipid-modified oligonucleotides [5, 6]. 
 
Figure 5. 20% denaturing polyacrylamide gels depicting the time course of the BSP-catalyzed 
degradation of unmodified (wt) and 5'-modified passenger strands 1-4. 
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